The exon-3 deletion of the growth hormone receptor (GHR) gene still has a limited impact in clinical endocrinology

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 1, 2010, Pages 56-59

  Bougneres P ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; SOMATOMEDIN C;

ACROMEGALY; EDITORIAL; EXON; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 75149134686     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2233     Document Type: Editorial

References (22)

1. Bernabeu I, Alvarez-Escolá C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M 2010 The exon-3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95:222-229
2. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S 2000 Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275:18664-18669
3. Bougneres PF, Artavia-Loria E, Ferre P, Chaussain JL, Job JC 1985 Effects of hypopituitarism and growth hormone replacement therapy on the production and utilization of glucose in childhood. J Clin Endocrinol Metab 61:1152-1157
4. Møller N, Jørgensen JO 2009 Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30: 152-177
5. Felig P, Lynch V 1970 [Starvation in human pregnancy: hypoglycemia, hypoinsulinemia, and hyperketonemia]. Science 170:990-992
6. Bass SH, Mulkerrin MG, Wells JA 1991 A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc Natl Acad Sci USA 88:4498-4502
7. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P 2004 A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720-724
8. Gimelbrant A, Hutchinson JN, Thompson BR, Chess A 2007 Widespread monoallelic expression on human autosomes. Science 318: 1136-1140
9. Sovio U, Bennett AJ, Millwood IY, Molitor J, O'Reilly PF, Timpson NJ, Kaakinen M, Laitinen J, Haukka J, Pillas D, Tzoulaki I, Molitor J, Hoggart C, Coin LJ, Whittaker J, Pouta A, Hartikainen AL, Freimer NB, Widen E, Peltonen L, Elliott P, McCarthy MI, Jarvelin MR 2009 Genetic determinants of height growth assessed longitudinally from infancy to adulthood in the northern Finland birth cohort1966. PLoS Genet 5:e1000409
10. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, Jones CG, Zaitlen NA, Varilo T, Kaakinen M, Sovio U, Ruokonen A, Laitinen J, Jakkula E, Coin L, Hoggart C, Collins A, Turunen H, Gabriel S, Elliot P, McCarthy MI, Daly MJ, Järvelin MR, Freimer NB, Peltonen L 2009 Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet 41:35-46
11. Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA 2009 Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient(GHD)and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab 94:3721-3730
12. Rosenfeld RG 2007 Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature. Eur J Endocrinol 157:S27-S31
13. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG 2002 American Norditropin Clinical Trials Group. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 87:90-98
14. Lotton C, Rodrigue D, Elie C, Rothenbühler A, Lahlou N, Le Stunff C, Bougnères P 2008 Akt phosphorylation in lymphocytes provides an index of in vitro insulin-like growth factor I sensitivity associated with growth hormone-induced growth. J Clin Endocrinol Metab 93:1458-1463
15. Schmid C, Krayenbuehl PA, Bernays RL, Zwimpfer C, Maly FE, Wiesli P 2007 Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin Chem 53:1484-1488
16. Montefusco L, Filopanti M, Ronchi CL, Olgiati L, La-Porta C, Losa M, Epaminonda P, Coletti F, Beck-Peccoz P, Spada A, Lania AG, Arosio M 10 September 2009 d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype. Clin Endocrinol (Oxf) doi: 10.1111/j.0300-0664.2009.03703. x
17. Kamenicky P, Dos Santos C, Espinosa C, Salenave S, Galland F, Le Bouc Y, Maison P, Bougnères P, Chanson P 2009 D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Eur J Endocrinol 161:231-235
18. Mercado M, González B, Sandoval C, Esquenazi Y, Mier F, Vargas G, de los Monteros AL, Sosa E 2008 Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab 93:3411-3415
19. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L 2009 Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015-2022
20. Higham CE, Trainer PJ 2008 Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol 93:1157-1169
21. Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A, De Marinis L 2009 Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 12:196-199
22. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (Pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723